Pharmacologic treatment of children and adolescents with impulsive aggression and related behaviors

2006 ◽  
pp. 297-314
Author(s):  
Dario Calderoni
Keyword(s):  
Children And Adolescents ◽  
Pharmacologic Treatment ◽  
Impulsive Aggression

Pharmacologic Treatment of Vitiligo in Children and Adolescents: A Systematic Review

2016 ◽  
Vol 34 (1) ◽  
pp. 13-24 ◽  
Author(s):  
Andreia Freire de Menezes ◽  
Fernanda Oliveira de Carvalho ◽  
Rosana S. S. Barreto ◽  
Bruno de Santana Silva ◽  
Saravanan Shanmugam ◽  
...  
Keyword(s):  
Systematic Review ◽  
Children And Adolescents ◽  
Pharmacologic Treatment

scholarly journals Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention

Neurology ◽  
2019 ◽  
Vol 93 (11) ◽  
pp. 500-509 ◽  
Author(s):  
Maryam Oskoui ◽  
Tamara Pringsheim ◽  
Lori Billinghurst ◽  
Sonja Potrebic ◽  
Elaine M. Gersz ◽  
...  
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Children And Adolescents ◽  
Behavioral Therapy ◽  
Pediatric Population ◽  
Cognitive Behavioral ◽  
Headache Frequency ◽  
Pharmacologic Treatment ◽  
Migraine Prevention ◽  
Pediatric Migraine ◽  
Pharmacologic Treatments

ObjectiveTo provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population.MethodsThe authors systematically reviewed literature from January 2003 to August 2017 and developed practice recommendations using the American Academy of Neurology 2011 process, as amended.ResultsFifteen Class I–III studies on migraine prevention in children and adolescents met inclusion criteria. There is insufficient evidence to determine if children and adolescents receiving divalproex, onabotulinumtoxinA, amitriptyline, nimodipine, or flunarizine are more or less likely than those receiving placebo to have a reduction in headache frequency. Children with migraine receiving propranolol are possibly more likely than those receiving placebo to have an at least 50% reduction in headache frequency. Children and adolescents receiving topiramate and cinnarizine are probably more likely than those receiving placebo to have a decrease in headache frequency. Children with migraine receiving amitriptyline plus cognitive behavioral therapy are more likely than those receiving amitriptyline plus headache education to have a reduction in headache frequency.RecommendationsThe majority of randomized controlled trials studying the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Recommendations for the prevention of migraine in children include counseling on lifestyle and behavioral factors that influence headache frequency and assessment and management of comorbid disorders associated with headache persistence. Clinicians should engage in shared decision-making with patients and caregivers regarding the use of preventive treatments for migraine, including discussion of the limitations in the evidence to support pharmacologic treatments.

Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescents

CNS Spectrums ◽  
2020 ◽  
pp. 1-9
Author(s):  
Adelaide S. Robb ◽  
Daniel F. Connor ◽  
Birgit H. Amann ◽  
Benedetto Vitiello ◽  
Azmi Nasser ◽  
...  
Keyword(s):  
Aggressive Behavior ◽  
Children And Adolescents ◽  
Clinical Outcomes ◽  
Unmet Needs ◽  
Assessment Tool ◽  
Aggressive Behaviors ◽  
Impulsive Aggression ◽  
Primary Disorder ◽  
Closing The Gap ◽  
Detrimental Impact

Abstract Impulsive aggressive (IA, or impulsive aggression) behavior describes an aggregate set of maladaptive, aggressive behaviors occurring across multiple neuropsychiatric disorders. IA is reactive, eruptive, sudden, and unplanned; it provides information about the severity, but not the nature, of its associated primary disorder. IA in children and adolescents is of serious clinical concern for patients, families, and physicians, given the detrimental impact pediatric IA can have on development. Currently, the ability to properly identify, monitor, and treat IA behavior across clinical populations is hindered by two major roadblocks: (1) the lack of an assessment tool designed for and sensitive to the set of behaviors comprising IA, and (2) the absence of a treatment indicated for IA symptomatology. In this review, we discuss the clinical gaps in the approach to monitoring and treating IA behavior, and highlight emerging solutions that may improve clinical outcomes in patients with IA.

Pharmacologic treatment of impulsive aggression with antiepileptic drugs

2009 ◽  
Vol 11 (5) ◽  
pp. 383-390 ◽  
Author(s):  
Matthew S. Stanford ◽  
Nathaniel E. Anderson ◽  
Sarah L. Lake ◽  
Robyn M. Baldridge
Keyword(s):  
Antiepileptic Drugs ◽  
Pharmacologic Treatment ◽  
Impulsive Aggression
Sign in / Sign up

Export Citation Format

Share Document